ArticleJournal of extracellular vesicles2020
Efficient and reproducible depletion of hepatitis B virus from plasma derived extracellular vesicles.
Article in Journal of extracellular vesicles, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Targeted blockade of extracellular vesicles-mediated profibrotic vicious circle using EVs-based dual-drug delivery system to prevent liver fibrosis.Journal of nanobiotechnology · 2025Article
- Harnessing crosstalk between extracellular vesicles and viruses for disease diagnostics and therapeutics.Extracellular vesicles and circulating nucleic acids · 2024Review
- Engineered small extracellular vesicles as a novel platform to suppress human oncovirus-associated cancers.Infectious agents and cancer · 2023Review
- Many Ways to Communicate-Crosstalk between the HBV-Infected Cell and Its Environment.Pathogens (Basel, Switzerland) · 2022Review
- Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment.Theranostics · 2022Review
- Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition.Seminars in immunopathology · 2021Review
- Blood Nanoparticles - Influence on Extracellular Vesicle Isolation and Characterization.Frontiers in pharmacology · 2021Review
- Extracellular Vesicles Regulated by Viruses and Antiviral Strategies.Frontiers in cell and developmental biology · 2021Review
- Efficient and reproducible depletion of hepatitis B virus from plasma derived extracellular vesicles.Journal of extracellular vesicles · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are emerging fundamental players in viral infections by shuttling viral components, mediating immune responses and likely the spread of the virus. However, the obstacles involved in purifying EVs and removing contaminating viral particles in a reliable and effective manner bottlenecks the full potential for the development of clinical and diagnostic treatment options targeting EV. Because of the similarities in size, density, membrane composition and mode of biogenesis of EVs and virions there are no standardized approaches for virus-removal from EV preparations yet. Functional EV studies also require EV samples that are devoid of antibody contaminants. Consequently, the study of EVs in virology needs reliable and effective protocols to purify EVs and remove contaminating antibodies and viral particles. Here, we established a protocol for EV purification from hepatitis B virus (HBV)-containing plasma by a combination of size-exclusion chromatography and affinity-based purification. After purification, EV samples were free of virus-sized particles, HBV surface antigen, HBV core antigen, antibodies or infectious material. Viral genomic contamination was also decreased following purification. By using appropriate antibodies and size parameters, this protocol could potentially be applied to purification of EVs from other viral samples. In summary, we established a fast, reproducible and robust approach for the removal of HBV from EV preparations. Looking forward to the point of purifying EVs from clinical samples, this method should enable studies shedding light on the underlying mechanisms of EVs in viral infections and their diagnostic and prognostic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.